Copy number variants (CNVs) at specific loci have been identified as important risk factors
for several neuropsychiatric disorders, such as schizophrenia, autism spectrum disorder …

In 1976, I (JTC) finished my psychiatric residency, received my first National Institutes of
Health grant, opened my laboratory, and took responsibility for the Schizophrenia Outpatient …

Background Schizophrenia (SCZ) and bipolar disorder (BIP) are debilitating
neuropsychiatric disorders, collectively affecting 2% of the world's population. Recognizing …

Advances in laboratory testing have significantly increased the detection of rare genetic
etiologies of neurodevelopmental psychiatric disorders (NPD), particularly developmental …

Schizophrenia is a severe mental illness that affects~ 1% of the world's population. It is
clinically characterized by positive, negative, and cognitive symptoms. Currently available …

Fear, anxiety, and trauma-related disorders, including post-traumatic stress disorder (PTSD),
are quite common and debilitating, with an estimated lifetime prevalence of~ 28% in …

Clinical characterization of a patient phenotype has been the quintessential approach for
elucidating a differential diagnosis and a hypothesis to explore a potential clinical diagnosis …

Treatment-resistant schizophrenia (TRS) or suboptimal response to antipsychotics affects
almost 30% of schizophrenia (SCZ) patients, and it is a relevant clinical issue with significant …

Complex genomic rearrangements (CGRs) are known contributors to disease but are often
missed during routine genetic screening. Identifying CGRs requires (i) identifying copy …

Background: Dysfunction of the N-methyl-D-aspartate glutamate receptor is involved in the
putative pathology of schizophrenia. There is growing interest in the potential of N-methyl-D …